1. Medtech Insight

GE expands Biosense Webster deal for ultrasound tech:

GE Healthcare and Biosense Webster have extended a long-standing strategic partnership, with the aim of developing real-time ultrasound imaging technology for use in electrophysiology procedures. The partnership, of which financials details were not revealed, will see GE combine its ultrasound imaging capabilities with EP catheter technology belonging to Diamond Bar, California-based Biosense Webster. GE claims the two companies are to co-develop imaging solutions specifically for intracardiac therapies. The companies had previously built an alliance in order to integrate GE's CardioLab IT system for electrophysiology recording with Biosense Webster's Carto mapping system.

GE Healthcare and Biosense Webster have extended a long-standing strategic partnership, with the aim of developing real-time ultrasound imaging technology for use in electrophysiology procedures. The partnership, of which financials details were not revealed, will see GE combine its ultrasound imaging capabilities with EP catheter technology belonging to Diamond Bar, California-based Biosense Webster. GE claims the two companies are to co-develop imaging solutions specifically for intracardiac therapies. The companies had previously built an alliance in order to integrate GE's CardioLab IT system for electrophysiology recording with Biosense Webster's Carto mapping system.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By Elizabeth Orr

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By Marion Webb

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.